$19.07
Innoviva is a biotechnology business based in the US. Innoviva shares (INVA) are listed on the NASDAQ and all prices are listed in US Dollars. Innoviva employs 112 staff and has a trailing 12-month revenue of around $330.5 million.
Our top picks for where to buy Innoviva stock
How to buy Innoviva stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – INVA. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Innoviva stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Innoviva stock price (NASDAQ: INVA)
Use our graph to track the performance of INVA stocks over time.Innoviva shares at a glance
Latest market close | $19.07 |
---|---|
52-week range | $12.22 - $19.45 |
50-day moving average | $17.77 |
200-day moving average | $16.01 |
Wall St. target price | $18.00 |
PE ratio | 10.9492 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $1.77 |
Is it a good time to buy Innoviva stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Innoviva price performance over time
Historical closes compared with the close of $19.07 from 2024-09-06
1 week (2024-08-30) | -1.60% |
---|---|
1 month (2024-08-07) | 5.13% |
3 months (2024-06-07) | 18.15% |
6 months (2024-03-07) | 26.46% |
1 year (2023-09-07) | 52.32% |
---|---|
2 years (2022-09-07) | 43.06% |
3 years (2021-09-07) | 23.91% |
5 years (2019-09-06) | 69.36% |
Is Innoviva stock undervalued or overvalued?
Valuing Innoviva stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innoviva's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innoviva's P/E ratio
Innoviva's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Innoviva shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Innoviva's PEG ratio
Innoviva's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.24. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Innoviva's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Innoviva's EBITDA
Innoviva's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $199.5 million.
The EBITDA is a measure of a Innoviva's overall financial performance and is widely used to measure a its profitability.
Innoviva financials
Revenue TTM | $330.5 million |
---|---|
Operating margin TTM | 54.74% |
Gross profit TTM | $276.1 million |
Return on assets TTM | 8.52% |
Return on equity TTM | 23.83% |
Profit margin | 44% |
Book value | $10.64 |
Market Capitalization | $1.2 billion |
TTM: trailing 12 months
Innoviva share dividends
We're not expecting Innoviva to pay a dividend over the next 12 months.
Have Innoviva's shares ever split?
Innoviva's shares were split on a 1241:1000 basis on 2 June 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1241 shares. This wouldn't directly have changed the overall worth of your Innoviva shares – just the quantity. However, indirectly, the new 19.4% lower share price could have impacted the market appetite for Innoviva shares which in turn could have impacted Innoviva's share price.
Innoviva share price volatility
Over the last 12 months, Innoviva's shares have ranged in value from as little as $12.22 up to $19.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innoviva's is 0.574. This would suggest that Innoviva's shares are less volatile than average (for this exchange).
Innoviva overview
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
Frequently asked questions
nullWhat percentage of Innoviva is owned by insiders or institutions?
Currently 1.071% of Innoviva shares are held by insiders and 120.255% by institutions. How many people work for Innoviva?
Latest data suggests 112 work at Innoviva. When does the fiscal year end for Innoviva?
Innoviva's fiscal year ends in December. Where is Innoviva based?
Innoviva's address is: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010 What is Innoviva's ISIN number?
Innoviva's international securities identification number is: US45781M1018 What is Innoviva's CUSIP number?
Innoviva's Committee on Uniform Securities Identification Procedures number is: 88338T104
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question